CALGARY, AB / CRWEPRESSRELEASE / September 3, 2015 /Avagenesis Corp. (CVE:VVA) (“Avagenesis” or the “Company”) is pleased to announce that its licensed bioprocessing and cell isolation system has received a Certificate of Registration for compliance with ISO 13485 and 9001 (the “ISO Certification”).
ISO Certification demonstrates to customers that the Company’s contracted commercially manufactured bioprocessing system to isolate stem cells and regenerative cells from adipose liposuction fat has been certified to applicable standards with rigorous quality assurance and is a quality product for global markets and leading researchers.
ISO 13485:2003 harmonizes medical device regulatory requirements for quality management systems. It demonstrates a company’s ability to provide medical devices and related services that consistently meet customer and regulatory requirements.
ISO 9001:2008 is a quality management system that consistently meets customer and applicable statutory and regulatory requirements. It aims to enhance customer satisfaction through the effective application of the system, including processes for continual improvement of the system and the assurance of conformity to customer and applicable statutory and regulatory requirements.
About Avagenesis Corp.
Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of cosmetic surgery and regenerative medical aesthetics. Avagenesis’ development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells using patent-pending and patented bioprocessing and cell isolation technology. For licensing and strategic reasons, all patent registrations, FDA registrations and other regulatory certificates are arranged through an exclusive licensing agreement with a related and affiliated company.
Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis’ current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk thatAvagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis.Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions containedherein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Alan Tam, PFP, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575